Seroquel in the Treatment of Dysphoric Hypomania in Bipolar II
Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
1. The primary objective of this study is to examine the efficacy of quetiapine (Seroquel)
in treatment of dysphoric hypomania in patients with Bipolar II disorder.
2. To evaluate the utility of Seroquel add-on treatment to decrease mixed depressive and
hypomanic symptoms.